Our findings provide further evidence that prior decline in lung function may not predict future disease progression for ILD patients, and elevate the need for molecular definitions of a progressive phenotype. Across ILD subtypes, certain shared pathobiologies may be present based on the molecular profile of certain biomarker groups observed. In particular, SP-D may be a common marker of pulmonary injury and future lung function decline across ILDs.
Keyphrases
- lung function
- interstitial lung disease
- cystic fibrosis
- chronic obstructive pulmonary disease
- air pollution
- pulmonary fibrosis
- end stage renal disease
- systemic sclerosis
- ejection fraction
- current status
- newly diagnosed
- chronic kidney disease
- multiple sclerosis
- prognostic factors
- pulmonary hypertension
- rheumatoid arthritis